Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
Have heard nothing, zero, zilch, nada
Tweet him back yourself- Or call him. You will get an honest reply. PJ has to be in the top 5 for approachable CEO's/Directors within the AIM market. I would actually be surprised if he is not the league leader.
someone obviously dislikes PJ (it blows hot and cold on the MTR board when his name is mentioned). Maybe a few on LSE but in general terms he is very highly regarded. Follow just his trading and you wont go far wrong if you wait for the right opportunity to buy in. Having met him on many occasions I would certainly vouch for him and often followed in on a trade (these are not day trades) Look at his MTR trading arm investments - slowly many coming home to roost. Return on investment would put many to shame
Notifiable positions in RRR, GGP, KGLD, EUA, GRL, OSU, OPRA,THR. On ASX they also have MOD but not sure of % due to placing dilution. There are also warrants which you can see on their website. Should not assume that they are selling all the family jewels
News seems very limited- anyone have any update
Very naive comment in my opinion and from someone who obviously does not know EB , understand the market or has researched the stock. This will only move positively on commencement of Phase 3 trials or if they pull something new out of the hat. Hopefully findo out tomorrow as they are in town I believe
Despite my earlier post I think there maybe an element of truth in the rumour as it is on the Spok website - see their news bulletin. Not in but wish you all the best .
actually called the company to ask them? I have not invested but would carry out some basic due diligence
its a P&D but one of the "promoters" on twitter was aimcasino - known scamming liar (who has blocked me btw) Not sure of the source of the news
its a P&D but one of the "promoters" on twitter was aimcasino - known scamming liar (who has blocked me btw) Not sure of the source of the news
The 6.60 trades are buys -
So where is the suspension RNS? Quiptel RTO
Hopefully this week was the first sign of the bottom being found. The key is for the "disgruntled" seller (a previous shareholder was not invited into the last placing if you were not aware) to have completed. Unfortunately I am not aware of what he is/was holding. BOD would like to buy at this level but concert party rules prevent this due to their existing % holding. For the record I have bought more this week (have some from the placing)
MG said recently he was going to concentrate on CHAL- Personally I see this change as a positive for both
Every stock and more so on AIM can be seen as a gamble (as can funds, bonds, FX etc). However Amryt has: 1. An approved product and ano in pipeline 2. A highly experienced and proven BOD whom could be sitting in nice safe seats on larger companies. 3. A very low MCAP in comparison with peers with (or without) an approved Orphan drug. Joe Wiley on Thursday pointed on (as per their presentation) GWP with 2 proven with MCAP of £1,245.53m and Fibrocell with zero approved and 1 at pre-clinical at $91.75m (actually presentation shows higher so I will email them) 4. BOD with very considerable investment. 5. Low free float Yes a gamble but an educated one with possibility of a very high return.
I personally would be amazed if there was an RNS on Monday with reference to the swing in price - which in reality returned it to the same closing as 2 weeks prior. The next news will or should be the appointment of a MO which is nearing conclusion and or the year end results which will mainly be Fastnet. The main selling since the RTO has been ex-Fast holders in most peoples opinion and with such a low free float I would have to agree. Pharma is a hard area to value but compared to peers with or without approved products Amryt is very considerably undervalued which will soon be recognised. Couple this with a BOD that has a great track record and I believe a trip back to the placing price is imminent.
I personally would be amazed if there was an RNS on Monday with reference to the swing in price - which in reality returned it to the same closing as 2 weeks prior. The next news will or should be the appointment of a MO which is nearing conclusion and or the year end results which will mainly be Fastnet. The main selling since the RTO has been ex-Fast holders in most peoples opinion and with such a low free float I would have to agree. Pharma is a hard area to value but compared to peers with or without approved products Amryt is very considerably undervalued which will soon be recognised. Couple this with a BOD that has a great track record and I believe a trip back to the placing price is imminent.
Their holding is just confirmation from the admission document- they have not purchased more
The £6m is a new rule effective as of this year- Companies listed previously as investment shells were exempt